NASDAQ:ALIM Alimera Sciences - ALIM News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Alimera Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.95 +0.10 (+5.41%) (As of 03/28/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.80▼$2.0050-Day Range$1.35▼$2.9452-Week Range$1.30▼$7.92Volume44,472 shsAverage Volume21,254 shsMarket Capitalization$13.65 millionP/E RatioN/ADividend YieldN/APrice Target$6.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Get Alimera Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter. Email Address ALIM Media Mentions By Week ALIM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALIM News Sentiment▼0.670.61▲Average Medical News Sentiment ALIM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALIM Articles This Week▼131▲ALIM Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineGlobal Non-Infectious Macular Edema Treatment Market to Reach $22.4 Billion by 2030finance.yahoo.com - March 28 at 1:09 PM8-K: ALIMERA SCIENCES INCmarketwatch.com - March 28 at 1:09 PMAlimera Sciences Shares Rise 18% After Capital Restructuringmarketwatch.com - March 27 at 1:45 PMAlimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facilityfinance.yahoo.com - March 27 at 1:45 PMProliferative Diabetic Retinopathy Market Share by 2031marketwatch.com - March 26 at 12:37 PMAlimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Updatefinance.yahoo.com - March 24 at 7:08 PMMacular Degeneration Treatment Global Market Report 2023finance.yahoo.com - March 24 at 2:07 PMDiabetic Retinopathy Market Outlook to 2028marketwatch.com - March 23 at 8:45 PMStockNews.com Initiates Coverage on Alimera Sciences (NASDAQ:ALIM)americanbankingnews.com - March 23 at 2:58 AMUveitis Treatment Market Size and Updated Report, Estimates & Forecast, By Application, segments 2023-2031marketwatch.com - March 22 at 11:07 PMOphthalmology Biologics Market Share and Forecast till 2031marketwatch.com - March 22 at 1:18 AMOcular Inflammation Treatment Market Growth and Forecast till 2028marketwatch.com - March 17 at 8:29 AMOcular Inflammation Treatment Market To Observer Consistent Development All through Forecast Period 2023-2030marketwatch.com - March 8 at 7:40 AM2023-2029 Retinal Vein Occlusion Market Size and Risks Factors Analysis | Survey Report by Absolute Reportsmarketwatch.com - March 2 at 7:38 AMAlimera Appoints Roger Sawhney, M.D. to Its Board of Directorsfinance.yahoo.com - February 27 at 10:42 AMAge-related Macular Degeneration Market Size 2023 with Pre COVID-19 and Post COVID-19 Market Scenario and Forecast till 2025marketwatch.com - February 23 at 5:03 PMH.C. Wainwright Reaffirms Their Buy Rating on Alimera (ALIM)markets.businessinsider.com - February 23 at 9:11 AMAlimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN®finance.yahoo.com - February 22 at 12:32 PMDiabetic Retinopathy Market Size Global Research Report, 2023 - 2028marketwatch.com - February 21 at 4:15 AMGlobal Ocular Inflammation Treatment Market Technology advancement and Latest Research Report 2023-2028marketwatch.com - February 20 at 7:17 AMIntravitreal (IVT) Injectables Market : Global Market Growth, New Trends, COVID-19 Impact and Forecast 2023 To 2028marketwatch.com - January 31 at 10:19 AMDiabetic Retinopathy Market International Business Analysis, Development Outlook and Regional Strategies 2028marketwatch.com - January 30 at 8:41 AMWet Age Related Macular Degeneration (AMD) Market Detailed Analysis of Current Industry Figures with Forecasts Regional Outlook 2028marketwatch.com - January 13 at 6:09 PMAlimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officerfinance.yahoo.com - January 9 at 1:05 PMDiabetic Retinopathy Market 2023 : Recent Developments, Industry Trends and Investigation Growth Rate, and Forecast to 2028marketwatch.com - January 5 at 6:23 AMAlimera Sciences, Inc. (NASDAQ:ALIM) Q3 2022 Earnings Call Transcriptfinance.yahoo.com - December 29 at 7:38 AMLooking Into Alimera Sciences's Return On Capital Employedmsn.com - December 23 at 12:38 PMWet Age Related Macular Degeneration (AMD) Market Provides an In-Depth Insight of Trends and Landscape Outlook 2022-2028marketwatch.com - December 12 at 7:12 AMAlimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan Agreementfinance.yahoo.com - December 8 at 9:52 AMAlimera Highlights Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN® Administrationfinance.yahoo.com - November 29 at 9:36 AM7 Stocks That Could Implode at Any Momentfinance.yahoo.com - November 25 at 1:59 AMGlobal Diabetic Retinopathy Market Report to 2027 - Featuring Bayer, Alimera Sciences, Novartis and Pfizer Among Others - ResearchAndMarkets.combusinesswire.com - November 23 at 12:37 PMAlimera Sciences Third Quarter 2022 Earnings: Misses Expectationsfinance.yahoo.com - November 16 at 6:49 AMAlimera Sciences, Inc. (ALIM) Q3 2022 Earnings Call Transcriptseekingalpha.com - November 15 at 2:45 AMAlimera Sciences, Inc.: Alimera Sciences Announces Third Quarter 2022 Financial Resultsfinanznachrichten.de - November 14 at 11:35 AMAlimera Sciences Announces Third Quarter 2022 Financial Resultsfinance.yahoo.com - November 14 at 11:35 AMAlimera Sciences (ALIM) Reports Q3 Loss, Lags Revenue Estimatesfinance.yahoo.com - November 14 at 11:35 AMAlimera Sciences Q3 2022 Earnings Previewseekingalpha.com - November 13 at 8:33 PMGlobal Diabetic Retinopathy Market Status and Trend 2022 Report by Competitive Landscape, Key Company Profiles, Types, Size and Forecast to 2028marketwatch.com - November 7 at 10:32 AMOcular Drug Delivery Technology Market Size, Sales, CAGR And Competition Data from 2022 To 2028marketwatch.com - November 5 at 4:56 AMAlimera Sciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022, and Provide Corporate Updatefinance.yahoo.com - November 2 at 9:23 AMAlimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in the Czech Republicfinance.yahoo.com - November 1 at 8:20 AMIs Alimera Sciences (ALIM) Stock Outpacing Its Medical Peers This Year?msn.com - October 20 at 11:47 AM10 Best Low Price Pharma Stocks To Buy Nowfinance.yahoo.com - October 18 at 9:20 AMPaladin Phase 4 Study Confirms ILUVIEN® Patients' Reduced Need for Multiple Treatmentsfinance.yahoo.com - October 6 at 12:16 PMAlimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Networkfinance.yahoo.com - September 23 at 10:25 AMAlimera Sciences Inc ALIM Stock Newsmorningstar.com - September 21 at 12:25 AMAlimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Irelandfinance.yahoo.com - September 20 at 7:25 PMAre Medical Stocks Lagging Alimera Sciences (ALIM) This Year?finance.yahoo.com - September 19 at 1:09 PMAre Medical Stocks Lagging Alimera Sciences (ALIM) This Year?finance.yahoo.com - September 19 at 1:09 PM Get Alimera Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:ALIM) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.